ABVC BioPharma Seeks To Revolutionize Mental Health Treatment With A Safe Prozac Alternative, Boasting A MADRS Score Reduction Of -13.21 From Baseline Over 6 Weeks With A Placebo-subtracted Difference Of -4.1
ABVC BioPharma Seeks To Revolutionize Mental Health Treatment With A Safe Prozac Alternative, Boasting A MADRS Score Reduction Of -13.21 From Baseline Over 6 Weeks With A Placebo-subtracted Difference Of -4.1
ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, today announced in response to the discontinuation of Prozac[1] due to increasing concerns around side effects, ABVC believes its ABV-1504, which has the API, "Radix Polygala", known as Polygala tenuifolia Willd or PDC-1421, can fill this void in the mental health market. With a robust formulation designed to reduce adverse effects, PDC-1421 promises to offer a safer and more effective solution for patients dealing with MDD and ADHD[2]. ABVC's ABV-1504 has completed Phase II clinical trials and is heading towards Phase III trials worldwide. ABVC holds patents for MDD and ADHD that have been approved in the USA and other countries and are valid until 2041.
ABVC BioPharma, Inc.（纳斯达克：ABVC）是一家临床阶段的生物制药公司，专注于眼科医疗、中枢神经系统（CNS）以及肿瘤/血液学的创新治疗。今天，针对由于对副作用的担忧不断增加而停用Prozac[1]，ABVC表示其ABV-1504，活性药物成分为“Radix Polygala”，也称为Polygala tenuifolia Willd或PDC-1421，能够填补心理健康市场的这一空缺。PDC-1421具有减少副作用的强效配方，承诺为应对重度抑郁症（MDD）和注意力缺陷多动障碍（ADHD）[2]的患者提供一个更安全、更有效的解决方案。ABVC的ABV-1504已经完成临床二期试验，并正在全球准备进入三期试验。ABVC拥有MDD和ADHD的专利，这些专利已在美国和其他国家获得批准，有效期至2041年。
The suspension of Prozac production highlights a rising demand for safer, all-natural alternatives to advanced mental health treatments, marking a pivotal moment for the pharmaceutical and mental health awareness industry. ABVC's ABV-1504 and 1505 have undergone rigorous clinical testing to ensure safety and efficacy, positioning them as real potential options for patients needing reliable, low-risk treatments.
Prozac生产的暂停突显出对更安全、全自然替代先进心理健康治疗的需求上升，这标志着药品和心理健康意识行业的一个关键时刻。ABVC的ABV-1504和1505经过严格的临床测试，以确保安全性和有效性，使它们成为需要可靠、低风险治疗的患者真正的潜在选择。
